Cryoport, Inc. (CYRX) SEC Filings & Earnings Calls

Dependence on CGT market growth and regulatory approvals; any slowdown could impact revenue.

“Revenue growth tied to clinical trial advancement and commercial therapy approvals”

Customer concentration

“One customer accounted for 11.2% of revenue during Q2 2026.”

Foreign exchange exposure

“Foreign currency translation adjustment of $(0.6) million for H1 2026.”

Convertible Senior Notes Maturity

“The 2026 Convertible Senior Notes payable of $186.2 million are due and payable in December 2026.” · word for word

Operating Losses

“Loss from operations $ (9,614) (thousands) for the three months ended March 31, 2026.”

Customer Concentration

“There was one customer that accounted for 10.8% of revenue during the three months ended March 31, 2026.” · word for word

Dependence on cell and gene therapy market growth

“Revenue tied to CGT clinical and commercial adoption.”

Execution risk on new global supply chain centers

“Planned launches in Paris and Santa Ana in 2026.”

Equity Dilution Risk

“If the Fourth Amendment is approved... total fully-diluted overhang of 13,495,469 shares (21.3% of our fully-diluted shares outstanding) under the 2018 Plan.”

Negative Adjusted EBITDA

“Adjusted EBITDA Target ($4.8M), Results ($5.8M), 83% of goal, 57% payout.”

High leverage and debt service risk

“As of December 31, 2025, we had approximately $262.4 million of indebtedness and other liabilities, including trade payables, on a consolidated basis.” · word for word

Historical losses and accumulated deficit

“As of December 31, 2025, we had an accumulated deficit of $688.9 million.” · word for word

Dilution risk from convertible securities

“Any subsequent conversion of shares of the Series C Preferred Stock to shares of our common stock would further dilute the ownership interest of existing holders of our common stock” · word for word

Blackstone preferred stock control and governance risk

“The Series C Preferred Stockholders may exercise influence over us, including through their right to nominate for election one member to our board of directors.” · word for word

Macro challenges impacting Life Sciences Products segment growth

“CEO noted 'macro challenges' affecting Products segment, which grew only 7%”

High Debt Level

“Total carrying value of Convertible Senior Notes, net $184,799k, due December 2026.” · word for word

Net Loss

“Income (loss) from continuing operations ($6,696k) vs $3,920k.”

Impairment Risk

“Impairment of trademarks and trade names recorded $9.0 million in prior period.”

Potential adverse impact from U.S. federal government shutdown on anticipated therapy approvals and filings.

“These anticipated approvals and filings may be adversely impacted by the current federal government shutdown in the United States.” · word for word